Perihan Warren
Family · Wilmington, NCNPI 1659755098
Payments from drug & device makers
Across 655 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$968
- Vanda Pharmaceuticals Inc.$950
- Neurocrine Biosciences, Inc.$515
- AbbVie$460
- plus $3K from 23 others
What the payments were for
- Consulting fees$1151%
- Food & beverage$9,95498%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 229 | $3,319 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,196 |
| Johnson & Johnson | 61 | $968 |
| Vanda Pharmaceuticals Inc. | 63 | $950 |
| Neurocrine Biosciences, Inc. | 32 | $515 |
| AbbVie | 33 | $460 |
| Lundbeck LLC | 14 | $272 |
| Corium, LLC | 22 | $232 |
| Otsuka America Pharmaceutical, Inc. | 12 | $223 |
| Almatica Pharma LLC | 15 | $220 |
| Alkermes, Inc. | 10 | $216 |
| Eisai Inc. | 18 | $212 |
| Supernus Pharmaceuticals, Inc. | 6 | $189 |
| Axsome Therapeutics, Inc. | 9 | $174 |
| Idorsia Pharmaceuticals US Inc | 11 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $149 |
| Bausch Health US, LLC | 8 | $127 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| E.r. Squibb & Sons, L.L.C. | 4 | $112 |
| Neos Therapeutics, LP | 6 | $87 |
| Sunovion Pharmaceuticals Inc. | 6 | $77 |
| Jazz Pharmaceuticals Inc. | 4 | $55 |
| Validus Pharmaceuticals LLC | 1 | $38 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Tris Pharma Inc | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$237
- CAPLYTA$130
- Austedo XR$109
How this compares
$10,183 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 70 | $474,602 |
| AustedoDeutetrabenazine | 30 | $266,441 |
| IngrezzaValbenazine Tosylate | 11 | $94,241 |
| RexultiBrexpiprazole | 29 | $77,837 |
| CaplytaLumateperone Tosylate | 39 | $71,802 |
| TrintellixVortioxetine Hydrobromide | 32 | $27,182 |
| VraylarCariprazine Hcl | 16 | $25,871 |
| LatudaLurasidone Hcl | 12 | $24,402 |
| Lisdexamfetamine Dimesylate | 38 | $13,854 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $13,049 |
| OzempicSemaglutide | 12 | $11,029 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,399 |
| EquetroCarbamazepine | 17 | $9,071 |
| Loreev XrLorazepam | 17 | $7,639 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 192 | $7,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $3,319 | $741,043100 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $515 | $94,24111 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $223 | $77,83729 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,196 | $71,80239 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $149 | $40,23157 claims |
| AbbVieVraylar | $460 | $25,87116 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $77 | $24,40212 claims |
| Validus Pharmaceuticals LLCEquetro | $38 | $9,07117 claims |
| Almatica Pharma LLCLoreev Xr | $220 | $7,63917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Wilmington
- Teresa DossWilmington$137K
- Courtney WilsonWilmington$81K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.